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Abstract 
 
 
RUNX transcription factors are a family of DNA-binding proteins that function in 
development and hematopoiesis.  Mixed Lineage Leukemias (MLL) are dependent on RUNX1 
for oncogenic activity, but it is unclear whether MLLs are also affected by RUNX2. In this 
project, RUNX2 was knocked down in a variety of MLL-derived cell lines using shRNAs, and 
the levels of leukemic cell apoptosis were monitored by FACS. If found to be required for MLL, 
this would identify RUNX2 as a new therapeutic target.  
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Background 
 
Leukemia Introduction 
The leukemias are a group of related cancers that usually begin in the bone marrow and 
result in high numbers of abnormal, non-fully differentiated white blood cells.  The symptoms 
may include bleeding and bruising, fatigue, fever, and an increased risk of infections.   
 
There are four main types of leukemia: acute lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia 
(CML). The acute leukemias are characterized by a rapid increase in the number of immature 
blood cells, and are the most common forms of leukemia in children. Immediate treatment is 
often necessary because of the swift progression and accumulation of the malignant cells, which 
then can enter the bloodstream and metastasize to other organs. The chronic leukemias occur 
mostly in older people, and are characterized by a relatively slow buildup of relatively mature yet 
abnormal white blood cells, taking up to months or even years to develop. Additionally, the 
leukemias are subdivided according to lineage of affected cells. Lymphoblastic, or lymphocytic 
leukemia, occurs when the cancerous change takes place in marrow cells that form lymphocytes; 
myeloid, or myelogenous leukemia, occurs when leukemia develops in marrow cells that mature 
into red blood cells, platelets, etc. 
 
Treatments of leukemia include chemotherapy, radiation therapy, targeted therapy, and 
bone marrow transplants. These treatment methods are often combined to maximize their 
effectiveness. Some chronic leukemias are managed with watchful waiting, or treating the 
symptoms of leukemia as they arise, in order to expose the patient to the minimum amount of 
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aggressive therapies as possible.  The success of treatment depends on age and the type of 
leukemia, and success has improved in developed countries (GBD, 2015). The average five-year 
survival rate of people in the United States is approximately 57%. For children under the age of 
15, the five-year survival rate is around 60-85%, and children that are cured are unlikely to 
relapse (World Cancer Report, 2014).  
 
The causes for most cases of leukemia are unknown; the few known causes discovered to 
date account for a minority of the cases. The different leukemias likely have different causes, 
with both inherited and environmental (non-inherited) factors involved (Hutter, 2010). Among 
adults, the known causes include smoking, natural and artificial ionizing radiation, prior 
chemotherapy, viruses (such as human T-lymphotropic virus), DNA mutagenizing chemicals 
(such as benzene and alkylating agents), and Down’s syndrome (Stass et al., 2000; Wiernik, 
2001).  Leukemia can also arise from chromosomal mutations such as inversions (where part of 
the chromosome is inverted) or translocations (the rearrangement of non-homologous 
chromosomes). In both cases, the chromosomal change can place two genes adjacent to each 
other in an abnormal position, causing a change in the protein coded by the genes such as a 
truncation or a fusion of two proteins (Muntean and Hess, 2012).  
 
Protein MLL 
Chromosome translocations that disrupt the mixed lineage leukemia 1 (MLL1) gene 
account for about 10% of all human acute leukemias (Muntean and Hess, 2012). The MLL-1 
protein is also known as histone-lysine N-methyltransferase-2A (KMT2A), acute lymphoblastic 
leukemia-1 (ALL-1), or zinc finger HRX (HRX) protein (Ziemin-van der Poel et al., 1991).  This 
histone methyltransferase associates with chromatin at regulatory elements, and is a positive 
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regulator of gene transcription.  MLL is 3969 amino acids long (Muntean and Hess, 2012), and is 
a mammalian homolog of the Drosophila trithorax group (trxG) proteins involved in 
segmentation and development (Muntean and Hess, 2012). Like the trxG proteins, MLL 
regulates the expression of Hox genes that regulate embryonic transcription (Muntean and Hess, 
2012). The Hox genes determine the regional identity of body parts along the anterior-posterior 
axis of the body during embryonic development (Nakamura et al., 2002). One of the specific 
aspects of development Hox genes are responsible for is normal hematopoiesis (Argiropoulos 
and Humphries, 2007). The exact mechanism by which Hox genes regulate hematopoiesis is 
unclear, but mis-regulation studies have shown that either up- or down-regulating Hox genes can 
lead to blocking differentiation and promoting leukemogenesis. As MLL is one of the regulators 
of these Hox genes, a mutation in MLL that impedes this regulation can cause leukemia 
(Argiropoulos and Humphries, 2007). 
Post-translationally, MLL protein is cleaved into two proteins: the N-terminal domain, 
and a shorter C-terminal domain, which non-covalently dimerize in the presence of a large 
protein complex (Wilkinson et al., 2013). MLL regulates gene transcription epigenetially through 
its methyltransferase activity (Wilkinson et al., 2013). The protein dimer contains several 
functional domains (Figure-1). The AT-hooks of the N-terminal domain (red in the diagram) 
non-specifically bind the DNA minor groove. The DNA methyltransferase homology region (the 
CxxC domain) specifically binds un-methylated DNA.  The SET domain of the C-terminal 
protein (blue in the diagram) is responsible for methylating the fourth lysine on Histone H3, 
which activates the transcription of target genes (Nakamura et al., 2002). In MLL leukemias 
(discussed in detail below), the binding of MLL to a translocation partner (diagram center, 
including AF4, AF6, AF9, or ENL) to form a fusion protein results in the loss of the C-terminal 
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domain of MLL. While the fusion protein likely retains the DNA-binding functions of the N-
terminal domain, it must use other conserved sequences in the N-terminal domain and the 
translocation partner to attempt to bind and activate its targets, thus it mis-regulates its targets or 
aberrantly targets other genes (Muntean and Hess, 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: The MLL Protein.  Shown are the domains of the WT 
MLL protein (diagram upper), and the structure of various MLL 
fusion proteins (diagram center) (Muntean and Hess, 2012). 
 
MLL Leukemogenesis 
MLL translocations account for about 10% of all acute leukemias in humans (Muntean 
and Hess, 2012). MLL has a wide range of translocation partners, including both nuclear and 
cytoplasmic proteins (Muntean, 2013). Although more than 60 different translocation partners 
are known, nine predominant partners make up about 90% of MLL translocation leukemias: AF-
1, AF-4, AF-6, AF-9, AF-10, AF-17, ENL, ELL, and SEPT-6 (Muntean and Hess, 2012). The 
distribution of these nine translocation partners in pediatric and adult MLL leukemias is shown 
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in Figure-2. For example, 85% of adult ALL leukemias result from MLL-AF4 translocations, 
while 35% of adult AML leukemias result from MLL-AF-9 translocations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Translocations in MLL-Type Leukemias. Shown are 
the frequency of translocation partners in pediatric and adult MLL 
leukemias (Muntean and Hess, 2012). 
 
 
Patients with MLL have mixed prognoses depending on the translocation partner, but in 
general, there is a low survival rate and high risk, so aggressive treatments are often used 
(Muntean and Hess, 2012).  
Leukemogenesis is the induction and development of leukemia in bone marrow. MLL 
fusion proteins can transform hematopoietic stem cells and intermediate progenitor cells into 
leukemic stem cells (Muntean, 2013). Leukemogenesis does not occur by simply truncating the 
MLL protein, indicating that the translocation partner is necessary for the disease phenotype 
(Muntean, 2013). Additionally, in vivo experiments have shown that MLL mutations require a 
latency period before leukemogenesis occurs, suggesting that additional mutations are necessary 
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for leukemogenesis. This supports the two hit theory that leukemia occurs from a combination of 
mutations in activated kinase pathways and DNA-binding proteins. In support of this theory, 
30% of pediatric MLL cases also involve Ras mutations (Muntean, 2013).  
MLL leukemias up-regulate Hox genes, especially Cluster-A Hox genes. Up-regulation of 
HoxA9 by MLL fusion proteins is the most highly correlated gene with poor prognosis for 
patients. In fact, an in vivo study showed that HoxA9 up-regulation was essential for the 
transformation of leukemic cells, showing that MLL fusion proteins are “Hox-dependent gain-of-
function mutants” (Ayton and Cleary, 2003). 
 
The RUNX Family of Transcription Factors 
The Runt-related family of transcription factors (RUNX, including RUNX1, RUNX2 and 
RUNX3) derive their name, and are homologous to runt, a segmentation gene in Drosophila (Ito, 
2004). The RUNX factors help regulate the differentiation of a variety of tissues, including the 
regulation of cell fate determination decisions of hematopoietic stem and progenitor cells into 
mature blood cells.  The family is also called core binding factor-α (CBFα). RUNX proteins 
form heterodimeric complexes with CBFβ which confers increased DNA binding and stability to 
the complexes. 
The three RUNX genes (Figure-3) share a common DNA-binding domain known as the 
Runt Homology domain (red in the diagram), and their proteins form heterodimers with their 
cofactor CBF (Cameron and Neil, 2004). In vivo data has shown that CBF is required for the 
proper function of all three RUNX proteins. CBF knockout embryos have null Runx function, 
and die at mid-gestation (at about day 11.5 after conception) with a lack of normal hematopoiesis 
(Wang et al., 1996; Cameron et al., 2003).  All three RUNX proteins, along with their cofactor 
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CBFb, regulate development of various types of progenitor cells at key decision points in the cell 
cycle, regulating the decision between proliferation, differentiation, and cell-death (Cameron and 
Neil, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Structure of the Three RUNX Family Transcription Factor Genes. 
The Runt domain common to all RUNX family members is shown as red in the 
diagram (Ito, 2004). 
 
Although the three RUNX proteins are very similar, they each have independent 
functions; knockout mice for any member either die during fetal development or are severely 
compromised from developmental defects (Cameron et al., 2003).  Perhaps the best characterized 
family member is RUNX1.  RUNX1, also known as acute myeloid leukemia-1 protein (AML1) 
or core-binding factor subunit alpha-2 (CBFA2), is a transcription factor that is required for the 
development of normal hematopoiesis, and for the differentiation of myeloid progenitors into 
granulocytes. It is also the most frequent target of chromosome translocations associated with 
AML (Ito, 2004).  RUNX1 was initially shown to have a role in leukemogensis when it was 
found to be a component of chromosomal translocation t(8:11), which occurs in acute myeloid 
leukemia (AML) (Erickson et al., 1992; Nisson et al., 1992; Miyoshi et al., 1993). Since this 
discovery, as many as ten other translocation fusion partners have been identified for RUNX1, 
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all resulting in a fusion and deactivation of the RUNX1 C-terminal transactivation domain 
(Cameron et al., 2003).  In all cases, the Runt Homology Domain, that binds DNA and CBF, is 
always conserved as part of the leukemia fusion protein. 
RUNX2 is required for the normal development of osteoblasts (Ito, 2004). RUNX2 has 
not yet been shown to be involved in any human cancers, however its deficiency has been linked 
to the development of cleidocranial dysplasia, a human bone disease (Ito, 2004). RUNX3 is 
involved in regulation of mature DC8+ T cells and in the development of the gastric epithelium 
(Cameron et al., 2004). 
 
The Roles of RUNX in Leukemogenesis 
RUNX proteins can participate in cancer either as direct fusion proteins or as targets of 
fusion proteins.  And RUNX genes can act both as oncogenes and tumor suppressors (Cameron 
and Neil, 2004). Tumor suppressor genes protect cells from the induction of cancer, and their 
functions are typically lost in cancer cells. Oncogenes are dominant genes whose functions 
promote cancer by activating mutations and transcriptional deregulations (Cameron and Neil, 
2004). In some instances, RUNX1 can act as a tumor suppressor; RUNX1 mutations caused by 
translocations that inactivate the protein have been found in cases of myeloid leukemia 
(Cameron et al., 2003). On the other hand, in a study of 41 children with acute lymphoblastic 
leukemia, enhanced RUNX1 levels were found in 43.9% of cases, showing that RUNX1 over-
expression might be an important factor in leukemogensis (Mikhail et al., 2002). In this case, the 
over-expressed RUNX1 acts as an oncogene. Similarly, it was found that experimental over-
expression of wildtype RUNX proteins has an oncogenic effect (Cameron et al., 2003). Cameron 
et al. showed that RUNX2 can also act as an oncogene in a dose-dependent way. After 
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amplifying RUNX2 expression using retroviral insertional mutagenesis to activate an enhancer, 
7% of mice heterozygous for the transgene developed lymphomas within 12 months, while 64% 
of homozygous mice developed lymphomas within 7 months (Cameron et al., 2003). 
RUNX1 has the dual ability to function as a tumor suppressor and pro-survival factor, 
and this function is dose-dependent in leukemogenesis (Figure-4). Wildtype cells (left side of 
the diagram) require a certain level of RUNX1 for normal hematopoiesis, and as stated before, 
over-expression of RUNX1 can have an oncogenic effect on cells (Cameron et al., 2003). When 
RUNX1 levels are reduced from wildtype levels (right side of the diagram), myeloid 
differentiation is blocked, leading to leukemia (diagram lower). This illustrates the tumor 
suppressor role of RUNX1 in cell development and maintenance that is lost with a loss-of-
function RUNX1 mutation (Goyama et al., 2013). However, it was found that a certain level of 
RUNX is necessary for the maintenance of leukemic cells; completely knocking out RUNX1 
leads to cell cycle arrest and death (diagram right). The cancer cells’ dependency on RUNX1 
shows the role of RUNX1 as a pro-survival factor, and identifies it as a potential therapeutic 
target (Goyama et al., 2013).  
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Figure-4: The Dose-Dependent Function of RUNX1 in 
Leukemogenesis. Shown is the dual role of RUNX1 as a tumor 
suppressor and pro-survival factor (Goyama et al., 2013). 
 
 
In MLL-AF4 leukemia (Figure-5), RUNX1 is over-expressed and is directly activated by 
the MLL-AF4 fusion protein (diagram left). RUNX1 then interacts with MLL-AF4 to activate its 
downstream targets (diagram right) (Wilkinson et al., 2013). Since RUNX1 promotes the 
survival of MLL-AF4 cells by activating target genes and regulating them, knocking down 
RUNX1 reduces the survival of these cells (Wilkinson et al., 2013).  
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Figure-5: The Role of RUNX1 in MLL-AF4 Leukemia. A 
chromosome translocation creates the MLL-AF4 fusion protein 
which activates RUNX1 (diagram left).  RUNX1 then interacts 
with MLL-AF4 and other proteins to activate its downstream 
targets (diagram right) (Wilkinson et al., 2013). 
 
 
Similarly, RUNX2 is a target of MLL-AF4 and AF9 fusion proteins, and is upregulated 
by binding the fusion protein to a proximal promoter of RUNX2 (Guenther et al., 2008; Bernt et 
al., 2011). If RUNX2 acts in a similar manner to RUNX1, it could be a potential therapeutic 
target to treat MLL-AF4 and –AF9 leukemias.   
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Project Purpose 
 
 
The RUNX transcription factors are a family of DNA-binding proteins that function in 
development and hematopoiesis.  Mixed Lineage Leukemias (MLL), involving translocations of 
the protein MLL, are dependent on RUNX1 for oncogenic activity, but it is unclear whether 
MLLs are also affected by RUNX2.  In MLL-AF4 leukemia, RUNX1 is directly activated by the 
MLL-AF4 fusion protein, and RUNX1 interacts with MLL-AF4 to activate downstream targets 
(Wilkinson et al., 2013). Since RUNX1 promotes the survival of MLL-AF4 cells by activating 
target survival genes, inhibiting RUNX1 reduces the survival of these cells (Wilkinson et al., 
2013).  Similarly, RUNX2 has been shown to be a target of MLL-AF4 and AF9 fusion proteins, 
and is upregulated by binding of the fusion protein to a proximal promoter of RUNX2 (Guenther 
et al., 2008; Bernt et al., 2011), but it is not known whether the leukemic cells also depend on 
RUNX2 for survival. In this project, the overarching hypothesis is that RUNX2 is directly 
upregulated by fusion protein MLL-AF9 and plays a role in the subsequent block of 
differentiation and the survival of the AML cells. We have reduced (knocked down) RUNX2 
expression in three MLL-derived cell lines using shRNAs, and the level of leukemic cell 
apoptosis was monitored by FACS for early apoptosis marker Annexin-V. If found to be 
required for MLL, this would identify RUNX2 as a new therapeutic target to treat MLL-AF4 and 
–AF9 leukemias.  
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Methods 
 
Cell Culture 
The three leukemic cell lines used for this study were MOLM-13, THP-1, and RS4;11 
cells, all were obtained from the ATCC. The MOLM-13 cell line originated from the peripheral 
blood of a patient with acute myeloid leukemia expressing the MLL-AF9 fusion. THP-1 cells are 
human monocytes with acute monocytic leukemia expressing MLL-AF9. RS4;11 cells are 
human lymphoblasts with acute lymphoblastic leukemia expressing the MLL-AF4 fusion. All 
three cell lines were grown as suspensions in T-25 flasks in complete RPMI medium (Gibco) 
containing 10% FBS (Clonetech) and 1% Pen-Strep (Gibco).  Cultures were incubated at 37°C in 
5% CO2. Cells were sub-cultured every 2-3 days, with the media changed and cells split as 
needed to maintain a concentration of 0.5-2.0 x 106 cells/mL.  
 
shRNA Sequencing 
Two samples of plasmid DNA containing the RUNX2 shRNAs [sh1 (TRCN0000013656) 
and sh3 (TRCN0000013654)] were obtained from the TRC library of RNAi core (UMMS). One 
plasmid containing a scrambled control insert (Scr, Plasmid #1864) was obtained from Addgene 
repository. In these plasmids, the puromycin marker was replaced by green fluorescent protein 
(GFP) in the Castilla lab for sorting purposes. The sequences of the two RUNX2 and scrambled 
shRNAs were originally designed and distributed by Dharmacon (Now Thermo Fischer 
Scientific, Inc.) and sequenced by us before using them in this project to verify their inserts.  
Samples of all three plasmids were sent to Eton Biosciences to be sequenced. These plasmid 
constructs were further used for making lentiviral particles. The sequences of sh1 and sh2 are 
shown below. 
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Sh1: TRCN0000013656 TAAGACTGGTCATAGGACCAC 
Sh3: TRCN0000013654   AATGCGCCCTAAATCACTGAG 
 
Lentivirus Production 
HEK293T cells were transfected with the shRNA plasmids and lentiviral packaging 
plasmids to produce transgenic lentiviruses containing the desired shRNAs. For each of the three 
plasmids (sh1, sh3, and scrambled control), three plates of 5x106 293T cells were transfected as 
follows: for each plate, 1.8 mL of Opti-MEM (Gibco) and 50 μL FuGENE transfection reagent 
(Promega) were added to a DNA mix made of 6 μg of psPAX lentiviral packaging plasmid, 3 ug 
MD2.G envelope-expressing plasmid, and 6 μg of the plasmid of interest. The mix was incubated 
for 15 minutes at room temperature, and then was added dropwise to the plate of cells. The plates 
were incubated overnight, and the medium from each plate was harvested and replaced with 
fresh complete DMEM medium every morning for the next 3 days. After all the media were 
harvested, 1 mL of Lentiviral concentrator (Clonetech) was added for every 3 ml virus 
supernatant, and it was incubated overnight at 4°C. The next day, the media samples were spun 
for 45 minutes at 1300 rpm in a Beckman Coulter Allegra 6KR centrifuge and re-suspended in 4 
mL fresh DMEM. The virus-containing medium was split into 1 mL aliquots and stored at  
-80°C.  
 
Transduction of Cell Lines 
2x106 cells were plated in each well of a 6-well plate. 45 μL HEPES buffer (Gibco), 1.5 
μL Polybrene, and a 1 mL aliquot of the virus containing the shRNA of interest were added to 
each well, and RPMI medium was added to bring the total volume of the well to 3 mL. Each 
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plate was spun for 90 minutes at 2500 rpm at 30°C, and then incubated for 5 hours at 37°C. After 
5 hours, the medium of each well was replaced with fresh RPMI medium.   
 
Sorting of Transduced Cells 
Cells were sorted by FACS at 48 hours post-transduction. They were spun for 5 minutes 
at 1300 rpm and resuspended in 500 μL sterile FACS buffer (sterile PBS with 0.1% BSA) per 
1x106 cells. Cells were filtered through a 37 micron filter mesh and kept on ice until sorting. 7-
AAD fluorophore, a dead cell marker, was added to cells at a concentration of 7 μL 7-AAD per 
500 μL FACS buffer. Cells were sorted on a “BD FACSARIA” FACS machine. Cells that were 
GFP positive (containing shRNA plasmid) and 7-AAD negative (viable) were selected and 
collected in PBS solution.  Sorted cells were seeded in 6-well plates at a concentration of 2x106 
cells per well, and fresh RPMI medium was added to bring the well volume to 3 mL. Cells were 
kept in the 37°C incubator and the medium was changed every 2 days. 
 
Dead Cell Removal 
Dead cells were removed from the cultures of sorted cells 24 hours after sorting using the 
Miltenyi Biotec Dead Cell Removal Kit following the manufacturer’s procedure. 
 
Annexin-V Assay 
After cell sorting, approximately 1x106 cells were cultured in 6-well plates. Cells were 
analyzed by FACS every 48 hours starting 24 hours after sorting (72 hours after transduction). 
Levels of GFP and an early-apoptosis marker, Annexin-V, were analyzed to monitor levels of 
apoptosis in cells transduced with the RUNX2 shRNAs until nine days after transduction.  Cells 
were analyzed by FACS as discussed above. Samples containing approximately 105 cells were 
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taken for cultures transduced with sh1, sh3, or the scrambled control, and non-transduced (NT) 
cells as a negative control. Medium was removed from each sample, and they were washed twice 
with 1 mL cold PBS. Cells were resuspended in 100 μL of 1X binding buffer and stained for 15 
minutes with 5 μL of PE-Annexin V and 5 μL of 7-AAD. After 15 minutes, cells were spun for 5 
minutes at 1300 rpm and resuspended in 200 μL fresh binding buffer. An Unstained control was 
made with a sample of NT cells to which no PE-Annexin V or 7-AAD was added. Single-stained 
compensation controls were prepared by taking a sample of sh1-transduced cells that remained 
unstained (to control for GFP), and taking two samples of NT cells and staining with 5 μL of 
either PE-Annexin V or 7-AAD. Cells were kept on ice after staining until analyzed on the 
FACS machine (BD LSRII). 
For FACS analysis, the unstained sample was run first to identify the cell population by 
forward (FSC-A) and side scatter (SSC-A) and to adjust the voltage levels as needed. Next, the 
three single control samples were run to determine the level of spectral overlap between the three 
fluorophores and to adjust the compensation for these overlaps. Finally, each of the four stained 
samples were run and the fluorescence was recorded.  
The FACS results were analyzed by first gating for live cells on a plot of forward scatter 
vs side scatter. Single cells were gated on a plot of FSC-A vs FSC-H.  A gate for GFP positive 
cells was created on a plot of FITC-A vs FSC-A, where FITC-A is the channel on which GFP 
fluoresces. Lastly, a plot of Per-C-P5.5 vs PE-A was used to calculating the percentage of cells 
in early apoptosis by calculating the population of PE-Annexin V positive and 7-AAD negative 
cells.  
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Western Blot 
After cell sorting, approximately 1x106 cells for each group (NT, scrambled, sh1, and 
sh3) of RS4;11 and THP-1 cell lines were lysed in 100 μL RIPA lysis buffer. The concentration 
of total protein in each lysate was assayed using a Bradford assay. Approximately 20 μg of 
protein was added to 5 μL of 5X SDS-PAGE dye, and samples were heated for 15 minutes at 
95°C. Samples were loaded onto a 10% PAGE gel, with 10 μL of a prestained protein marker 
(Broad Spectrum, Life Technologies) loaded alongside the samples. The gel was run at 60 V 
until samples were about halfway down the gel, at which point the voltage was increased to 100 
V, and the electrophoresis was continued until the marker dye reached the bottom of the gel. The 
protein was transferred from the gel to a PVDF membrane by trans-blotting at 100 V for 90 
minutes in 1X transfer buffer at 4°C. The blot was then blocked for 1 hour with 0.5% milk 
protein in 0.1% TbsT, and then probed for RUNX2, RUNX1, or ERK (as a loading control), 
using 10 μL of each primary antibody purchased from Cell Signaling Technologies and 0.2 μL of 
anti-rabbit IgG secondary antibody. Blots were processed and developed on an X-ray film using 
enhanced chemiluminescent solutions (Millipore). 
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Results 
 
 
To test the hypothesis that knocking down RUNX2 will increase the levels of apoptosis 
in MLL leukemic cells, RUNX2 was knocked down via shRNAs in one MLL-AF4 and two 
MLL-AF9 cell lines. The approach used was to: 1) sequence the shRNA RUNX2 plasmids to 
verify the inserts, 2) determine the level of RUNX2 knockdown using western blots, and 3) 
analyze the cell lines by FACS for changes in apoptosis and cell death.  
 
shRNA Sequencing 
First, the two shRNA-containing plasmids used for RUNX2 knockdown (sh1 and sh3) 
were obtained from Emmanuel Bikorimana, a postdoc in the Castilla laboratory, and were then 
sent to Eton Biosciences. The results of the sequencing are shown in Figure-6.  
 
 
 
 
 
Figure-6: Sequence of RUNX2 shRNA Inserts for Plasmids sh1 and 
sh3.  Shown are the desired sequences of sh1 and sh3 (blue), and the 
results of the sequencing experiment of the plasmids containing each 
insert (black). The forward shRNA sequence is shown in yellow, and the 
reverse complement (to make the hairpin) is shown in green. 
 
Since shRNAs have a hairpin turn to be functional, they contain a palindrome repeat, so 
there should be a forward shRNA sequence and its reverse complement. The sequences of the 
forward sequence are shown in yellow, and the reverse complement strands of the shRNAs are 
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highlighted in green. As can be seen, both of the sequences highlighted in green are the exact 
reverse complements of the forward shRNA sequences. The forward sequence for sh1 almost 
exactly matches the known desired sequence of sh1 (blue in the diagram). Since both the forward 
and reverse complementary sequences are almost exact matches of the known sequence, this can 
be considered a reasonably positive identification result, indicating that the plasmid thought to 
contain sh1 indeed contains the sh1 insert. The forward (yellow) sequence for sh3 is not an exact 
match for the desired sequence, but over half of the nucleotides match. Since the reverse 
complement was an exact match of the known sequence, this can also be considered a reasonably 
positive identification of the sh3 insert. It is possible that the two insert sequences did not exactly 
match the known desired sh1 and sh3 sequences due to mutations that incurred in our lab during 
cloning and amplification of the plasmids, but we deem this unlikely because the plasmid 
sequences originally obtained in our lab matched perfectly the desired sequence.  We deem it 
more likely that the rapid sequencing done here was not entirely accurate, especially as it had to 
be done multiple times to get a relatively clean read. In any case, the sequences were considered 
close enough to warrant continuing ahead with the knockdown experiments, since the purpose of 
the sequencing was merely to identify the shRNA plasmids as not being the scrambled control. 
 
 
 
Quantification of RUNX2 Knockdown 
Three MLL-fusion cell lines (THP-1, MOLM-13, and RS4;11) were transduced with sh1, 
sh3, a scrambled control, or the pLKO vector control as described in Methods. After sorting for 
transduced cells on Day-2 by GFP FACS and removing dead cells using a dead cell removal kit 
on Day-3, approximately 1x106 cells per condition were obtained.  These cells were lysed in 
RIPA buffer, and total cellular protein was analyzed on a Western blot to assay the level of 
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RUNX2 protein knockdown induced by the shRNAs. 1x106 cells of each non-transduced cell 
line were also analyzed as a control to show the levels of WT RUNX2 expression. The resulting 
blots are shown in Figure-7 for the RS4;11 and THP-1 cell lines; there were not enough MOLM-
13 cells recovered from the sorting after setting aside 1x106 cells for FACS analysis to run a blot.  
 
 
 
 
 
 
 
 
 
 
 
Figure-7: Western Blot Analyses for Transduced Cell Lines to 
Measure RUNX2 Knockdown.  Shown are Western blots for RUNX2, 
RUNX1, and ERK Control for non-transduced cells (lane NT), and cells 
transduced with scrambled plasmid (Scr), sh1, and sh3, for RS4;11 cells 
(left column) and THP-1 cells (right column). Cells transduced with the 
pLKO vector control were not included on these blots. 
 
The blots were probed for RUNX2 to show levels of knockdown, RUNX1 to see if there 
was any effect on another RUNX family member, and ERK 1/2 as a loading control to show the 
relative amounts of protein loaded on the gel; expression of ERK should not change due to 
RUNX2 knockdown. Unfortunately, the levels of ERK were not the same for each condition in 
either cell line. So, either ERK was a poor choice of loading control, or there were problems 
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loading the same amounts of total protein. More protein was loaded for the non-transduced cells 
than the other conditions, and there appears to be less protein loaded for the sh3 condition for 
THP-1 cells. Since there were varying amounts of protein loaded between conditions, the amount 
of information that can be gained from this blot is limited. Due to time constraints, a better blot 
was not able to be produced.  In the future, a blot with the same amounts of total protein load per 
lane should be done, or a different load marker should be tested.  
Aside from the differences in loaded protein, there appears to be a decrease in the level of 
RUNX2 expression in the sh1 group of THP-1 cells compared to the scrambled control. These 
two conditions appear to have approximately the same level of ERK, so it is likely that RUNX2 
was successfully knocked down by sh1. Sh3 also appears to be knocked down compared to the 
scrambled control in THP-1 cells, but there was a much lower level of ERK for sh3, so this 
apparent knockdown might be just a lower level of protein loaded. Similarly, there is no apparent 
change in levels of RUNX2 in RS4;11 cells, or of RUNX1 in either cell line, except for the NT 
lane showing some degradation of RUNX2 for an unknown reason, but the varying levels of 
ERK show that these results might be faulty.  While the results of this blot are difficult to 
interpret, they provide preliminary evidence that sh1 knocked down RUNX2 in the THP-1 cells.  
Since the loading of the blot was faulty, quantification of the knockdown levels cannot be 
determined.  
 
 
GFP and Annexin-V FACS Assays 
Three leukemic cell lines (THP-1, MOLM-13, and RS4;11) were transduced with sh1, 
sh3, the scrambled control, or the pLKO vector control as described in Methods. After sorting for 
transduced cells via GFP and removing dead cells, approximately 1x106 cells per condition per 
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cell line were obtained.  These cells were placed in culture, and starting on Day-3 (72 hours after 
transduction), cells were assayed for levels of apoptosis using FACS for Annexin-V every 48 
hours until Day-9. The experiment was originally performed without sorting for GFP-positive 
cells on Day-2, but it was impossible to tell from the initial set of data whether the apoptosis 
levels resulted from RUNX2 knockdown. So, the GFP sort was introduced to remove the 
background from cells that were not successfully transduced.  
The experiment was repeated using the GFP pre-sorting procedure for transduced cells.  
Time did not allow the sorted experiment to be done in triplicate, so only data from N=1 is 
reported here for the three cell lines. First, the percentage of GFP-positive (GFP+) cells was 
analyzed by FACS (Figure-8). The Y-axis represents GFP (Comp-FITC-A, the fluorophore 
associated with GFP), and the X-axis represents FSC-A (the amount of light scattered by the cell, 
which corresponds to cell size). The population of GFP+ cells was gated to exclude most, if not 
all, of the cells in the non-transduced condition.  The THP-1 cells show approximately 91.1% 
transduction after sorting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-8: Analysis of Percent Transduced Cells.  Non-transduced THP-1 cells (left 
panel) and cells transduced with plasmid pLKO (right panel) were analyzed on Day-3 by 
FACS for GFP (Comp-FITC fluorophore associated with GFP) (Y-axis), and for FSC-A 
(light scattering, X-axis, corresponding to cell size).   
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Graphs of GFP (Comp-FITC-A) vs. light scatter (FSC-A) for all conditions of all three 
cell lines on Days 3, 5, 7, and 9 were gated for GFP in the manner described above, and the 
percentage of cells defined as GFP+ were recorded (Figure-9).  
 
Figure-9: Percentage of GFP+ Cells for Each Cell Line.  Shown is the 
GFP+ FACS analysis of three leukemic cell lines (THP-1, MOLM-13, 
and RS4;11) measured on Days 3, 5, 7, and 9 post-transduction with the 
plasmid listed on the X-axis.  Note: The Day-9 data for the pLKO control 
group for each cell line were not able to be collected, so were omitted 
from these graphs. Each histobar represents N=1. 
 
As can be seen in the graphs, all three cell lines showed a decrease in GFP+ cells in the 
sh1 group: THP-1 cells showed a 33% decrease in GFP+ cells by Day-9 (compared to the levels 
of GFP+ cells in the sh1 group on Day-3), MOLM-13 cells showed a 46% decrease, and RS4;11 
cells showed a 36% decrease. There was no significant change in the percentage of GFP+ cells in 
the other groups in any cell line. The scrambled control group for MOLM-13 cells shows a 
decrease in GFP+ cells on Day 5 and 9, but since not many viable cells were recovered in this 
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group, these decreases may represent error than an actual loss of GFP+ cells. Additionally, there 
was no significant decrease in % GFP+ cells in the sh3 groups of any of the cell lines, indicating 
that sh3 was likely not as effective at knocking down RUNX2 levels, as was suggested by the 
Western blot data described above. Assuming the percent GFP+ cells is high in strongly viable 
cells, the GFP+ FACS data also allow indirect conclusions to be made about cell viability.  In 
each cell line, the cells transduced with sh1 show a greater decrease in % GFP+ cells than either 
of the control groups. Since the GFP+ cells represent the cells that were successfully transduced 
and express the shRNA, this decrease in % GFP+ cells shows that when RUNX2 is knocked 
down in cells, they are less viable than cells without RUNX2 knockdown. This supports the 
hypothesis that decreasing levels of RUNX2 in MLL cells results in cell death.  
 Next, the levels of cells in apoptosis were analyzed by FACS after staining with 
Annexin-V, an early apoptosis marker, and 7-AAD, a dead cell marker.  The percentage of cells 
that were Annexin-V positive and 7-AAD negative (in apoptosis but not dead yet) were recorded 
for each condition on Days 3, 5, 7, and 9 (Figure-10). The FACS data shows Comp-PerCP-Cy5-
5-A (the fluorophore associated with 7-AAD) on the y-axis, and Comp-PE-A (the fluorophore 
associated with Annexin-V) on the x-axis. Gates were set for both axes based on the fluorescence 
for non-transduced cells not stained with either marker, so most cells should lie underneath each 
gate.  These gates were maintained for all subsequent experiments.  As shown in the right panel, 
most of the leukemic cells in the scrambled control group appeared in the Annexin+, 7-AAD- 
quadrant, indicating that they were in early apoptosis, as expected.  
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Figure-10: FACS Analysis of Annexin-V and 7-AAD.  Shown are non-transduced 
THP-1 cells (left panel) and cells transduced with control plasmid pLKO (right panel) on 
Day-3. The Y-axis represents Comp-PerCP-Cy5-5-A (the fluorophore associated with 7-
AAD, a cell death stain), and the X-axis denotes the fluorescence of Comp-PE-A (the 
fluorophore associated with Annexin-V, early apoptosis marker). 
 
 
 
Graphs of Comp-PerCP-Cy5-5-A (7-AAD) vs. Comp-PE-A (Annexin-V) for all 
conditions in 3 cell lines were analyzed on Days 3, 5, 7, and 9, using the gates described above.  
The percentage of cells defined as Annexin-V+ and 7-AAD- (early apoptosis) were determined 
(Figure-11) (data from the final experiment done).  As can be seen in the figure, there was no 
significant change in the percentage of Annexin-V+, 7-AAD- cells in any condition of any of the 
cell lines, suggesting that none of the RUNX2 shRNA plasmids affected apoptosis. The only 
notable change was that the sh1 group of THP-1 cells shows a 14% decrease in Annexin-V+, 7-
AAD- cells on Day-9 compared to Day-3. Also, it is important to note that the control plasmid 
pLKO group of RS4;11 cells shows much lower levels of Annexin-V+, 7-AAD- cells than the 
other conditions, suggesting the empty vector itself may increase apoptosis as well as the sh 
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RNAs. However, very few viable cells were recovered from this sorting, so the data cannot be 
considered highly accurate.  
 
Figure-11: Percentage of Annexin-V-Positive and 7-AAD-Negative Cells in Early 
Apoptosis for Three Leukemic Cells Lines. Shown are the FACS percentages of 
Annexin-V+, 7-AAD- cells for each leukemic cell line (THP-1, MOLM-13, and RS4;11) 
measured on Days 3, 5, 7, and 9 post-transduction. Note: The Day-9 data points for the 
pLKO group for each cell line were not able to be collected and so were omitted from 
these graphs 
 
 
The data analyzed from this part of the experiment does not support the hypothesis that 
knocking down RUNX2 causes an increase in cell apoptosis. None of the sh1 or sh3 groups of 
any of the cell lines showed a significant increase in the percentage of cells that bound Annexin-
V, a marker of early apoptosis, compared to cells transduced with scrambled plasmid. It is 
interesting to note that although there was no apparent change in apoptosis levels, all conditions 
except the non-transduced cells showed very high levels of apoptosis from Day-3. The non-
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transduced cells started between 20-40% Annexin-V+, 7-AAD- cells on Day-3, while the other 
groups started at 80-90% of Annexin-V+, 7-AAD- cells. These high levels of apoptosis from the 
start of analysis leaves little room for any further increases in apoptosis. It was expected that the 
control groups transduced with pLKO plasmid would show similar levels of apoptosis to the 
non-transduced cells, but the pLKO groups show much higher levels, indicating the control 
pLKO vector or the transduction process itself may cause cell toxicity.  
 
 
 
 
 
 
  
 32 
Conclusions and Future Experiments 
 
 
Leukemia is a devastating disease, and the search for better treatments is imperative. It 
has previously been found that while under-expression of RUNX1 contributes to 
leukemogenesis, those leukemic cells depend on the existing, yet low, level of RUNX1 for 
survival, and inhibiting RUNX1 entirely can cause cell cycle arrest and cell death (Goyama et 
al., 2013). RUNX1 functions in this manner in certain types of MLL leukemia, and is actually a 
target of the MLL fusion protein in MLL-AF4 (Wilkinson et al., 2013). This project aimed to 
determine whether RUNX2, a target of MLL-AF4 and -AF9, also functions as a pro-survival 
factor for the leukemic cells; if so, it could be a potential therapeutic target. 
Two RUNX2 shRNAs (sh1 and sh3) cloned into pLKO plasmids were used to attempt to 
knock down RUNX2 in three MLL leukemic cell lines. The results showed that cells transduced 
with sh1 likely knocked down for RUNX2, and die more rapidly in culture than cells transduced 
with the scrambled control shRNA or empty pLKO vector. However, analyzing the levels of 
apoptosis markers expressed by the cells showed equally high levels of apoptosis in all groups, 
both control and experimental, suggesting that the pLKO vector or the method of transduction is 
inducing apoptosis and killing the cells. This was not the expected result, and neither supports 
nor refutes the hypothesis, since the effect of RUNX2 knockdown on apoptosis could not be 
determined.  
There are several ways in which this experiment could be optimized or changed to better 
test the hypothesis. First, since even the vector control showed high levels of apoptosis, a 
different plasmid vector could be used to transduce cells with the shRNAs. There are a multitude 
of different commercially available expression cloning vectors to use other than the pLKO 
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plasmid used here. In addition, the cells could be tested with the transduction procedure without 
any plasmid to determine whether the procedure itself significantly increases apoptosis. 
Another way to solve the vector control problem would be to use a different method 
entirely of knocking down RUNX2. For example, instead of using a shRNA, an inhibitor could 
be used to treat cells to inhibit the expression or activity of RUNX2. When using an inhibitor, the 
time it takes for the compound to inhibit the target protein, the length of time of inhibition, and 
the half-life of the compound must be taken into account, but inhibitors can often be effective in 
studies such as this. However, there are no commercially available RUNX2 inhibitors at the 
moment, so until one becomes available another method must be used. Another method such as 
using CRISPR technology could be used to completely excise the RUNX2 gene. This could be a 
more effective, if not more time consuming, way to ensure lower expression of RUNX2 in the 
experimental groups compared to the controls. Another approach would be to use either CRISPR 
or shRNAs to knock down RUNX2 levels using an inducible expression system that allows the 
cells to initially recover from the transduction procedure, and then later initiate the knock down 
using an inducing compound. 
In addition to resolving the problem with the controls, further experiments need to be 
done to analyze the effects of different levels of knockdown on apoptosis. As is shown in Figure 
4 in the Background illustrating the effects of decreasing levels of RUNX expression, lower 
levels of RUNX in leukemic cells can cause cell death. By inducing varying levels of RUNX2 
knockdown in cells, perhaps by using different doses of an inhibitor, it could be determined 
whether the level of RUNX2 expression is proportional to the amount of cell death or if there is 
some threshold level of RUNX2 that separates whether cells survive or apoptose. This 
knowledge could inform future studies of RUNX2 inhibitors, if RUNX2 is indeed a therapeutic 
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target, of the level of RUNX2 inhibition needed to kill cells. Additionally, in vivo studies and 
studies using primary leukemic cell samples could be done to show the effects of RUNX2 
knockdown in a tumor microenvironment closer to that of a patient. These experiments might 
provide results that lead to better therapies for MLL leukemias.  
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